Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Piclidenoson in moderate/severe COVID-19
NCT04333472Phase 2Completed
- Sponsor
- Can-Fite BioPharma Ltd.
- Start
- Jan 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of piclidenoson in coronavirus disease 2019 (COVID-19), sponsored by Can-Fite BioPharma Ltd.. Started Jan 2021; status: completed.
02
Drugs
piclidenoson
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04333472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04333472.